Navigation Links
DEXILANT (dexlansoprazole) Product Information Updated Regarding Coadministration with Plavix (clopidogrel bisulfate)
Date:11/17/2011

ANT combines an enantiomer of lansoprazole with a Dual Delayed Release (DDR) formulation designed to provide two separate releases of medication. DEXILANT is indicated for healing all grades of erosive esophagitis (EE) for up to 8 weeks, maintaining healing of EE and relief of heartburn for up to 6 months, and treating heartburn associated with symptomatic non-erosive GERD for 4 weeks.

Important Safety Information

DEXILANT is contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity and anaphylaxis have been reported with DEXILANT use. Symptomatic response with DEXILANT does not preclude the presence of gastric malignancy. Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine. Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated. Hypomagnesemia has been reported rarely with prolonged treatment with PPIs.

Most commonly reported adverse reactions were diarrhea (4.8%), abdominal pain (4.0%), nausea (2.9%), upper respiratory tract infection (1.9%), vomiting (1.6%), and flatulence (1.6%). Do not co-administer atazanavir with DEXILANT because atazanavir systemic concentrations may be substantially decreased. DEXILANT may interfere with absorption of drugs for which gastric pH is important for bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole). Patients taking concomitant warfarin may require monitoring for increases in international normalized ratio (INR) and prothrombin time. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Concomitant tacrolimus use may increase tacrolimus whole blood concentrations.

Please see accompanying f
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
2. Data Presented at DDW About Rebound Symptoms in Healed Erosive Esophagitis Patients After Completion of Treatment with DEXILANT(TM) (dexlansoprazole)
3. Proton Pump Inhibitor DEXILANT(TM) (dexlansoprazole) Now Available in U.S. Pharmacies
4. KAPIDEX(TM) (dexlansoprazole) Renamed DEXILANT(TM) in U.S. to Avoid Name Confusion
5. New Study Results Analyzed the Use of KAPIDEX(TM) (dexlansoprazole) for Nighttime Heartburn in Adults with Non-Erosive GERD
6. White Smile Global Inc. Corporate Update on the White Smile Premier™ "At-Home" LED Teeth Whitening System and the White Smile Tooth Gloss™, Including Clinical Study, Product Manufacturing, and Distribution
7. 72 Prominent Personalized Medicine Products Available; A Five-Fold Increase in Five Years
8. Novation Awards ICU Medical, Inc. a New Contract to Supply Members With a Complete Line of Clinically-Preferred Critical Care Products
9. Landauer, Inc. Announces Acquisition of IZI Medical Products, LLC
10. Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH
11. Apelon Provides Products and Services to Support Canadian Healthcare Data Standardization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 2015  HyGreen, Inc., a leader in hand hygiene monitoring, ... Medical, a subsidiary of Ascendis Health Limited, in ... year, hundreds of millions of patients around the world ... transmitted from patient to patient via the unwashed hands ...
(Date:1/23/2015)... 2015 Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC ...  filed a Preliminary Proxy Statement, Schedule 14A, with the U.S. ... an update for shareholders detailing why a "YES" vote to ... Dear Shareholders, As we reflect upon the 2014 ...
(Date:1/23/2015)... 23, 2015 Gem Pharmaceuticals announced today that the ... into the Company,s Phase 2 clinical trial.  This open-label ... lead compound, GPX-150 (an investigational medication), in approximately 30 ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
Breaking Medicine Technology:HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has been ... business is showing its latest designs of wedding dresses and ... the company’s CEO, all the fresh new products are designed ... up to 80% off. All the clothes from LunaDress follow ...
(Date:1/22/2015)... is a seasoned and trusted leader who consistently delivers trendy ... have it lead the wedding dress industry into the future. ... for the global market. , “The CEO of VogueQueen is ... on continuing the goal of operational excellence and giving back ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... 22, 2015 For over 20 years, Dr. David ... and Vista area has treated just about every type of ... circumstances. And for those same twenty-plus years, the team at ... those injuries with the best possible doctor. With the ...
(Date:1/22/2015)... 2015 Recently, Weddingshe.com has added many trendy ... announced its highest annual revenues in the past three years. ... glamorous wedding dresses. , According to the sales manager of ... promotions for them in 2015. This point can be reflected ...
Breaking Medicine News(10 mins):Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... treatments to prevent lower limb amputations in diabetes - which ... Diabetes UK). , The research from the University of Bristol ... funded by the British Heart Foundation (BHF) and the European ... have serious complications like gangrene and skin ulcers due to ...
... the list; over 2,500 neighborhoods ranked, SEATTLE, ... company,that operates walkability site http://www.walkscore.com, today ... Most Walkable,Neighborhoods. With gas topping $4 per gallon, ... The new list is the first objective,national ranking ...
... held medical device manufacturer focusing on minimally invasive ... that the company has closed a Series C ... capital firms active in medical technology. The lead ... Partners and were joined in the round by ...
... Action applauds the,Senate for overwhelming, bipartisan passage ... Tuberculosis, and Malaria Reauthorization Act,(S 2731), which ... Relief,(PEPFAR). The organization particularly commends the lifting ... immigration to the U.S. by HIV,positive non-citizens. ...
... 16 While Lorillard Tobacco,Company (a wholly-owned subsidiary of ... the opportunity to fully review the latest report from ... that the report reaffirms,its view with respect to the ... including that:, -- "The available [scientific] evidence remains ...
... The following is a,statement by Tom Epstein, Vice President, ... the Los Angeles City Attorney is totally without,merit., ... by two,state agencies that have aggressively defended the interests ... seized on a hot topic in an,attempt to advance ...
Cached Medicine News:Health News:Insight into mechanisms of diabetes-induced microvascular disease reveals new therapies 2Health News:Walk Score Unveils America's Most Walkable Neighborhoods 2Health News:Vertos Medical Inc. Completes Series C Financing 2Health News:Vertos Medical Inc. Completes Series C Financing 3Health News:Vertos Medical Inc. Completes Series C Financing 4Health News:Lorillard Tobacco Company Comments on Harvard School of Public Health Report 2Health News:Lorillard Tobacco Company Comments on Harvard School of Public Health Report 3Health News:Statement Regarding Los Angeles City Attorney Enforcement Action 2
... Model 6495 Bipolar Coaxial Temporary Pacing Lead ... bipolar technology based on the sensing and ... Unipolar Temporary Pacing Lead., ,The Streamline Temporary ... temporary sensing and pacing during and after ...
... of temporary sensing and pacing leads. Our ... temporary pacing leads and improved upon the ... and less traumatic to heart tissue. , ... to provide consistent temporary sensing and pacing ...
... device was designed specifically to obviate the ... The eNcloseII device can provide the surgeon ... better hemodynamics as compared to partial occlusion ... suggested that complete or partial clamping of ...
... Carpentier-Edwards Classic annuloplasty rings have ... choice for more than 30 ... restore the anatomical size and ... to help prevent recurrent dilatation. ...
Medicine Products: